These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36778274)

  • 1. Clinical outcomes for pleomorphic xanthoastrocytoma patients: an institutional experience.
    Sullivan J; Chandler J; Lesniak M; Tate M; Sonabend A; Kalapurakal J; Horbinski C; Lukas R; Kumthekar P; Sachdev S
    Res Sq; 2023 Feb; ():. PubMed ID: 36778274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.
    Tonse R; Gupta T; Epari S; Shastri JG; Gurav M; Bano N; Jalali R
    J Neurooncol; 2018 Jan; 136(2):343-350. PubMed ID: 29147864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
    Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
    World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
    Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
    Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Grade on Survival in Pleomorphic Xanthoastrocytoma and Low Prevalence of BRAF V600E Mutation.
    Gandham EJ; Goyal-Honavar A; Beno D; Pai R; Balakrishan R; Jasper A; Gowri M; Moorthy RK; Chacko AG; Chacko G
    World Neurosurg; 2022 Aug; 164():e922-e928. PubMed ID: 35618235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?
    Vaubel R; Zschernack V; Tran QT; Jenkins S; Caron A; Milosevic D; Smadbeck J; Vasmatzis G; Kandels D; Gnekow A; Kramm C; Jenkins R; Kipp BR; Rodriguez FJ; Orr BA; Pietsch T; Giannini C
    Brain Pathol; 2021 Jan; 31(1):20-32. PubMed ID: 32619305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
    Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
    Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleomorphic Xanthoastrocytoma: Multi-Institutional Evaluation of Stereotactic Radiosurgery.
    Düzkalir AH; Samanci Y; Nabeel AM; Reda WA; Tawadros SR; Abdelkarim K; El-Shehaby AMN; Emad RM; Martínez Moreno N; Martínez Álvarez R; Mathieu D; Niranjan A; Lunsford LD; Wei Z; Shanahan RM; Liscak R; May J; Dono A; Blanco AI; Esquenazi Y; Dayawansa S; Sheehan J; Tripathi M; Shepard MJ; Wegner RE; Upadhyay R; Palmer JD; Peker S
    Neurosurgery; 2024 Jun; ():. PubMed ID: 38940575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of outcome in pleomorphic xanthoastrocytoma.
    Dono A; Lopez-Rivera V; Chandra A; Lewis CT; Abdelkhaleq R; Sheth SA; Ballester LY; Esquenazi Y
    Neurooncol Pract; 2021 Apr; 8(2):222-229. PubMed ID: 33898055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
    Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
    Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleomorphic xanthoastrocytomas: institutional experience of 18 patients.
    Oh T; Kaur G; Madden M; Bloch O; Parsa AT
    J Clin Neurosci; 2014 Oct; 21(10):1767-72. PubMed ID: 24950906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleomorphic xanthoastrocytoma: long-term results of surgical treatment and analysis of prognostic factors.
    Gallo P; Cecchi PC; Locatelli F; Rizzo P; Ghimenton C; Gerosa M; Pinna G
    Br J Neurosurg; 2013 Dec; 27(6):759-64. PubMed ID: 23514331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
    Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
    Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleomorphic Xanthoastrocytoma: a single institution retrospective analysis and a review of the literature.
    Detti B; Scoccianti S; Maragna V; Lucidi S; Ganovelli M; Teriaca MA; Caini S; Desideri I; Agresti B; Greto D; Buccoliero AM; Puppa AD; Sardi I; Livi L
    Radiol Med; 2022 Oct; 127(10):1134-1141. PubMed ID: 35951279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and surgical outcomes of high grade pleomorphic xanthoastrocytomas: a single-center experience with a systematic review.
    Zuo P; Li T; Sun T; Wu W; Wang Y; Zhang M; Wu Z; Zhang J; Zhang L
    Front Oncol; 2023; 13():1193611. PubMed ID: 37448517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritumoral Edema Affects the Prognosis in Adult Pleomorphic Xanthoastrocytoma: Retrospective Analysis of 25 Patients.
    Byun J; Hong SH; Kim YH; Kim JH; Kim CJ
    World Neurosurg; 2018 Jun; 114():e457-e467. PubMed ID: 29545226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grade II Pleomorphic Xanthoastrocytoma; a meta-analysis of data from previously reported 167 cases.
    Mallick S; Benson R; Melgandi W; Giridhar P; Rath GK
    J Clin Neurosci; 2018 Aug; 54():57-62. PubMed ID: 29803334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of spinal ependymomas: an institutional experience of more than 60 cases.
    Savoor R; Sita TL; Dahdaleh NS; Helenowski I; Kalapurakal JA; Marymont MH; Lukas R; Kruser TJ; Smith ZA; Koski T; Ganju A; Sachdev S
    J Neurooncol; 2021 Jan; 151(2):241-247. PubMed ID: 33179213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
    Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
    J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: a SEER analysis.
    Perkins SM; Mitra N; Fei W; Shinohara ET
    J Neurooncol; 2012 Oct; 110(1):99-104. PubMed ID: 22843450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.